4.2 Review

Endogenous cannabinoids revisited: A biochemistry perspective

Journal

PROSTAGLANDINS & OTHER LIPID MEDIATORS
Volume 102, Issue -, Pages 13-30

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.prostaglandins.2013.02.002

Keywords

Endocannabinoids; Anandamide; 2-Arachidonylglycerol

Funding

  1. Fundacao para a Ciencia e Tecnologia (FCT) [SFRH/BPD/72958/2010, SFRH/BD/70721/2010, SFRH/BD/81561/2011]
  2. Fundação para a Ciência e a Tecnologia [SFRH/BD/70721/2010, SFRH/BD/81561/2011] Funding Source: FCT

Ask authors/readers for more resources

Marijuana is the most commonly used illegal drug, particularly in Western societies. The discovery of an endogenous cannabinoid system (ECS) highlighted new molecules in various physiological processes. The ECS consists of G-protein-coupled cannabinoid receptors that can be activated by small lipid mediators, termed endocannabinoids (eCBs) and cannabis-derived drugs, plus the associated biochemical machinery (precursors, synthesis and degradative enzymes, and transporters). Several biochemical, pharmacological and physiological studies have shown that endocannabinoid system elements are widely distributed throughout the body, with regional variations and organ-specific actions. This review portrays the endocannabinoid family on new studies concerning eCB storage, release and functional roles and on the growing importance of its bioactive metabolites. Those findings reinforce and confirm the importance of ECS. Strategies for manipulating the system for the treatment of human disease will require a thorough understanding of the roles of the different eCBs and their sources. (C) 2013 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available